Suppr超能文献

雷诺现象治疗的进展。

Advances in the treatment of Raynaud's phenomenon.

作者信息

Levien Terri L

机构信息

College of Pharmacy, Washington State University Spokane, WA, USA.

出版信息

Vasc Health Risk Manag. 2010 Mar 24;6:167-77. doi: 10.2147/vhrm.s4551.

Abstract

Raynaud's phenomenon is a common condition characterized by vasospasm of the digital arteries and resulting cyanosis and redness. It often does not require pharmacologic management, but in some cases symptoms are severe and pharmacologic management is necessary. Calcium channel blockers are often used first-line, but in some patients are ineffective. Patients with severe symptoms or intolerance to available therapies have prompted exploration of alternative therapies, including endothelin antagonists, phosphodiesterase-5 inhibitors, antioxidants, newer vasodilators, statins, and botulinum toxin. These newer therapies provide the focus for this review.

摘要

雷诺现象是一种常见病症,其特征为指动脉血管痉挛,继而出现发绀和发红。通常无需药物治疗,但在某些情况下症状严重,药物治疗则必不可少。钙通道阻滞剂常作为一线用药,但在部分患者中无效。症状严重或对现有疗法不耐受的患者促使人们探索替代疗法,包括内皮素拮抗剂、磷酸二酯酶-5抑制剂、抗氧化剂、新型血管扩张剂、他汀类药物和肉毒杆菌毒素。这些新型疗法是本综述的重点。

相似文献

1
Advances in the treatment of Raynaud's phenomenon.
Vasc Health Risk Manag. 2010 Mar 24;6:167-77. doi: 10.2147/vhrm.s4551.
2
[Evidence-based therapy of Raynaud's syndrome].
Z Rheumatol. 2006 Jul;65(4):285-9. doi: 10.1007/s00393-006-0068-x.
3
Raynaud's phenomenon: Current concepts.
Clin Dermatol. 2018 Jul-Aug;36(4):498-507. doi: 10.1016/j.clindermatol.2018.04.007. Epub 2018 Apr 10.
4
Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis.
Joint Bone Spine. 2011 Jul;78(4):341-6. doi: 10.1016/j.jbspin.2010.11.005. Epub 2010 Dec 22.
5
Vasodilators for primary Raynaud's phenomenon.
Cochrane Database Syst Rev. 2021 May 17;5(5):CD006687. doi: 10.1002/14651858.CD006687.pub4.
6
Recent achievements in the management of Raynaud's phenomenon.
Vasc Health Risk Manag. 2010 Apr 15;6:207-14. doi: 10.2147/vhrm.s5255.
7
Nonoperative treatment of digital ischemia in systemic sclerosis.
J Hand Surg Am. 2012 Sep;37(9):1907-9. doi: 10.1016/j.jhsa.2012.02.009. Epub 2012 Apr 5.
8
Raynaud's Syndrome: a neglected disease.
Int Angiol. 2016 Apr;35(2):117-21. Epub 2015 Feb 12.
10
Treatment of Raynaud's phenomenon.
Autoimmun Rev. 2008 Oct;8(1):62-8. doi: 10.1016/j.autrev.2008.07.002. Epub 2008 Aug 8.

引用本文的文献

1
A systematic review of botulinum toxin as a treatment for Raynaud's disease secondary to scleroderma.
Clin Rheumatol. 2025 Jan;44(1):81-96. doi: 10.1007/s10067-024-07237-3. Epub 2024 Nov 30.
2
Raynaud's Phenomenon: A Current Update on Pathogenesis, Diagnostic Workup, and Treatment.
Vasc Specialist Int. 2024 Jul 23;40:26. doi: 10.5758/vsi.240047.
3
Blood vessels in a dish: the evolution, challenges, and potential of vascularized tissues and organoids.
Front Cardiovasc Med. 2024 Jun 13;11:1336910. doi: 10.3389/fcvm.2024.1336910. eCollection 2024.
4
Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon.
Cochrane Database Syst Rev. 2023 Nov 6;11(11):CD014089. doi: 10.1002/14651858.CD014089.
5
Iloprost for the treatment of frostbite: a scoping review.
Int J Circumpolar Health. 2023 Dec;82(1):2189552. doi: 10.1080/22423982.2023.2189552.
6
Raynaud's Phenomenon with Focus on Systemic Sclerosis.
J Clin Med. 2022 Apr 28;11(9):2490. doi: 10.3390/jcm11092490.
7
Raynaud's Phenomenon: Reviewing the Pathophysiology and Management Strategies.
Cureus. 2022 Jan 28;14(1):e21681. doi: 10.7759/cureus.21681. eCollection 2022 Jan.
8
Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review.
Toxins (Basel). 2021 Feb 5;13(2):120. doi: 10.3390/toxins13020120.

本文引用的文献

1
Oral sildenafil in skin ulcers secondary to systemic sclerosis.
Scand J Rheumatol. 2011;40(4):323-5. doi: 10.3109/03009742.2011.569755. Epub 2011 Jun 6.
2
Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.
Rheumatology (Oxford). 2010 Dec;49(12):2420-8. doi: 10.1093/rheumatology/keq291. Epub 2010 Sep 12.
3
Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study.
Ann Rheum Dis. 2010 Aug;69(8):1475-8. doi: 10.1136/ard.2009.116475. Epub 2009 Nov 8.
4
Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.
J Rheumatol. 2009 Oct;36(10):2264-8. doi: 10.3899/jrheum.090270. Epub 2009 Sep 15.
6
Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon.
J Hand Surg Am. 2009 Mar;34(3):446-52. doi: 10.1016/j.jhsa.2008.11.026.
8
Effects of bosentan on the skin lesions: an observational study from a single center in Japan.
Rheumatol Int. 2009 May;29(7):769-75. doi: 10.1007/s00296-008-0789-z. Epub 2008 Nov 27.
10
Raynaud's phenomenon: pathogenesis and management.
J Am Acad Dermatol. 2008 Oct;59(4):633-53. doi: 10.1016/j.jaad.2008.06.004. Epub 2008 Jul 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验